Fonadelpar

Summary

Fonadelpar (CHEMBL3545186) is a phase-3 clinical-stage small molecule; indicated across 1 condition including dry eye syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 504.5 Da · C25H23F3N2O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545186
Name	Fonadelpar
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9827461
Molecular formula	C25H23F3N2O4S
Molecular weight	504.5
InChIKey	WWKYLBGQYALEDL-UHFFFAOYSA-N

SMILES: CC1=CC2=C(C=C1OCC(=O)O)ON=C2CCC3=C(N=C(S3)C4=CC=C(C=C4)C(F)(F)F)C(C)C

IUPAC name: 2-[[5-methyl-3-[2-[4-propan-2-yl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]ethyl]-1,2-benzoxazol-6-yl]oxy]acetic acid

Also known as: Fonadelpar, NPS-005, SJP-0035, FONADELPAR

Patent coverage: 16 distinct patent families (71 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
dry eye syndrome	3	MONDO:0006733	EFO:1000906

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03527212	PHASE3	COMPLETED	A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).